Across TCGA pan-cancer cohorts, LCN15 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LCN15 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher LCN15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCN15 expression acts as an unfavorable survival marker.
SARC are the cancer types where LCN15 Mutation most reproducibly stratifies survival.